2
Clinical Trials associated with AUR-108A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR108 in Patients With Relapsed Advanced Lymphomas(ASHA-1)
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
A Phase 1, Open Label, Dose Escalation, Dose Expansion, MulticenterStudy Evaluating the Safety, Pharmacokinetics and Pharmacodynamicsof Oral AUR108 in Patients with Relapsed Advanced Lymphomas(ASHA-1) - ASHA-1
100 Clinical Results associated with AUR-108
100 Translational Medicine associated with AUR-108
100 Patents (Medical) associated with AUR-108
100 Deals associated with AUR-108